| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 618 | 2016 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma ES Gray, H Rizos, AL Reid, SC Boyd, MR Pereira, J Lo, V Tembe, ... Oncotarget 6 (39), 42008, 2015 | 346 | 2015 |
| Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma JH Lee, GV Long, S Boyd, S Lo, AM Menzies, V Tembe, A Guminski, ... Annals of Oncology 28 (5), 1130-1136, 2017 | 313 | 2017 |
| Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy SY Lim, JH Lee, TN Gide, AM Menzies, A Guminski, MS Carlino, EJ Breen, ... Clinical Cancer Research 25 (5), 1557-1563, 2019 | 300 | 2019 |
| Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies JH Lee, GV Long, AM Menzies, S Lo, A Guminski, K Whitbourne, ... JAMA oncology 4 (5), 717-721, 2018 | 273 | 2018 |
| Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition JH Lee, E Shklovskaya, SY Lim, MS Carlino, AM Menzies, A Stewart, ... Nature communications 11 (1), 1897, 2020 | 205 | 2020 |
| Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial GV Long, RPM Saw, S Lo, OE Nieweg, KF Shannon, M Gonzalez, ... The Lancet Oncology 20 (7), 961-971, 2019 | 153 | 2019 |
| Evaluation of commercial kits for purification of circulating free DNA RJ Diefenbach, JH Lee, RF Kefford, H Rizos Cancer genetics 228, 21-27, 2018 | 122 | 2018 |
| Liquid biomarkers in melanoma: detection and discovery SY Lim, JH Lee, RJ Diefenbach, RF Kefford, H Rizos Molecular cancer 17, 1-14, 2018 | 96 | 2018 |
| Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients JH Lee, RP Saw, JF Thompson, S Lo, AJ Spillane, KF Shannon, ... Annals of Oncology 30 (5), 815-822, 2019 | 86 | 2019 |
| Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors JH Lee, AM Menzies, MS Carlino, AC McEvoy, S Sandhu, AM Weppler, ... Clinical Cancer Research 26 (15), 4064-4071, 2020 | 61 | 2020 |
| Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma JHJ Lee, M Lyle, AM Menzies, MMK Chan, S Lo, A Clements, MS Carlino, ... Pigment Cell & Melanoma Research 31 (3), 404-410, 2018 | 54* | 2018 |
| Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy G Marsavela, J Lee, L Calapre, SQ Wong, MR Pereira, AC McEvoy, ... Clinical Cancer Research 26 (22), 5926-5933, 2020 | 50 | 2020 |
| PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges J Lee, R Kefford, M Carlino Immunotherapy 8 (6), 733-746, 2016 | 38 | 2016 |
| Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients SY Lim, JH Lee, SJ Welsh, SB Ahn, E Breen, A Khan, MS Carlino, ... Biomarker research 5, 1-12, 2017 | 35 | 2017 |
| Tumor MHC expression guides first-line immunotherapy selection in melanoma E Shklovskaya, JH Lee, SY Lim, A Stewart, B Pedersen, P Ferguson, ... Cancers 12 (11), 3374, 2020 | 30 | 2020 |
| Monitoring melanoma using circulating free DNA RJ Diefenbach, JH Lee, H Rizos American Journal of Clinical Dermatology 20 (1), 1-12, 2019 | 28 | 2019 |
| COVID-19: the use of immunotherapy in metastatic lung cancer AP Davis, M Boyer, JH Lee, SC Kao Immunotherapy 12 (8), 545-548, 2020 | 25 | 2020 |
| Pretreatment innate cell populations and CD4 T cells in blood are associated with response to immune checkpoint blockade in melanoma patients MR Pirozyan, HM McGuire, AA Emran, HY Tseng, JC Tiffen, JH Lee, ... Frontiers in immunology 11, 372, 2020 | 25 | 2020 |
| Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia HY Kim, JK Duong, M Gonzalez, GV Long, AM Menzies, H Rizos, SY Lim, ... Cancer Chemotherapy and Pharmacology 83, 693-704, 2019 | 25 | 2019 |
Helen RizosMacquarie UniversityVerified email at mq.edu.au
Helen RizosMacquarie UniversityVerified email at mq.edu.au